Evidence map›Paper›PMID 7517617›Full record

ArticleAgents and actions1993

NK1 receptors mediate tachykinin-induced plasma extravasation in the rat knee joint.

Y Hirayama, R Yasumitsu, A Kawamura, T Fujii

Abstract read
PubMed Publisher
In one paragraph

Article in Agents and actions, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Involvement of tachykinin receptors in oedema formation and plasma extravasation induced by substance P, neurokinin A, and neurokinin B in mouse ear.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 1996
    Article
  3. Involvement of substance P as a mediator in capsaicin-induced mouse ear oedema.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 1995
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Y HirayamaPharmacological Research Laboratory, Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan.
R Yasumitsu
A Kawamura
T Fujii

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tachykinin receptor type that mediates tachykinin-induced plasma extravasation in the rat knee joint was identified by using selective antagonists as well as natural or synthetic agonists. Substance P (SP) and neurokinin (NK) A induced plasma extravasation with almost the same potency and the maximum response was obtained at 5 nmol/knee. NKB was about ten times less potent than SP or NKA. The NK1 selective agonist, [Sar9, Met(O2)11]-SP, was about ten times more potent than SP, and the NK2 selective agonist, [Nle10]-NKA4-10, was about fifty times less potent than NK1 agonist. The NK3 agonist, Senktide, was totally ineffective at 0.5-50 nmol/knee. All responses induced by SP (5 nmol/knee), NKA (5 nmol/knee), NKB (50 nmol/knee), NK1 agonist (0.5 nmol/knee) or NK2 agonist (25 nmol/knee) were significantly and profoundly inhibited by the NK1 selective antagonist, RP67580, but not by the NK2 selective antagonist, SR48968. Taken together, we conclude that tachykinin-induced plasma extravasation in the rat knee joint is mediated via NK1 receptors.

Indexed as

AnimalsBenzamidesCapillary PermeabilityEvans BlueHindlimbIndolesIsoindolesJointsMaleNeurokinin-1 Receptor AntagonistsNeurokinin APiperidinesRatsRats, WistarReceptors, Neurokinin-1Receptors, Neurokinin-27,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-oneBenzamidesEvans BlueIndolesIsoindolesNeurokinin-1 Receptor AntagonistsNeurokinin APiperidinesReceptors, Neurokinin-1Receptors, Neurokinin-2SR 48968Substance PTachykinins

Identifiers

PMID7517617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.